The serum concentrations of leptin and MCP-1 independently predict low back pain duration
-
Giuseppe Lippi
,
Concetta Dagostino
Abstract
Background:
Low back pain (LBP) is a very frequent condition, affecting most people at some point throughout their life. This cross-sectional study was aimed to investigate a selected panel of cytokines and inflammatory biomarkers in patients with or without LBP.
Methods:
The study population consisted of 104 patients diagnosed with LBP (52 non-persistent and 52 persistent) and 52 healthy subjects with no LBP. Blood samples were collected for assessment of adiponectin, leptin, monocyte chemoattractant protein-1 (MCP-1) and C reactive protein (CRP). The duration of LBP was categorized as “no pain”, “non-persistent LBP” and “persistent LBP”.
Results:
Higher values of CRP and lower concentrations of both leptin and MCP-1 were found in LBP patients compared to controls, whereas adiponectin did not differ among groups. MCP-1 was also lower in patients with non-persistent than in those with persistent LBP. Age, leptin (relative risk, 11.8; 95% CI, 3.9–35.8) and MCP-1 (relative risk, 2.7; 95% CI, 1.7–4.4) were independently associated with presence and duration of LBP. The combination of age, leptin and MCP-1 predicted 61% of the risk of LBP duration. The area under the curve of MCP-1 for distinguishing persistent from non-persistent LBP was 0.65 (95% CI, 0.54–0.76).
Conclusions:
Then results of our study suggest that leptin and MCP-1 may be promising biomarkers for diagnosis of acute LBP and its risk to become chronic.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: The study was supported by a grant (602736 PainOmics) of European Community (Call of Proposal FP7-HEALTH-2013-INNOVATION-1 – Topic: HEALTH.2013.2.2.1-5 – Understanding and controlling pain).
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Koes BW, van Tulder MW, Thomas S. Diagnosis and treatment of low back pain. Br Med J 2006;332:1430–4.10.1136/bmj.332.7555.1430Suche in Google Scholar
2. Allegri M, Montella S, Salici F, Valente A, Marchesini M, Compagnone C, et al. Mechanisms of low back pain: a guide for diagnosis and therapy. F1000Res. 2016;5: pii (F1000 Faculty Rev-1530). doi: 10.12688/f1000research.8105.1.10.12688/f1000research.8105.1Suche in Google Scholar
3. Meucci RD, Fassa AG, Faria NM. Prevalence of chronic low back pain: systematic review. Rev Saude Publica 2015;49.10.1590/S0034-8910.2015049005874Suche in Google Scholar
4. Hoy D, Brooks P, Blyth F, Buchbinder R. The Epidemiology of low back pain. Best Pract Res Clin Rheumatol 2010;24:769–81.10.1016/j.berh.2010.10.002Suche in Google Scholar
5. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2163–96.10.1016/S0140-6736(12)61729-2Suche in Google Scholar
6. Haldeman S, Dagenais S. A supermarket approach to the evidence-informed management of chronic low back pain. Spine J 2008;8:1–7.10.1016/j.spinee.2007.10.009Suche in Google Scholar PubMed
7. Chou R, Qaseem A, Snow V, Casey D, Cross JT Jr, Shekelle P, et al. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med 2007;147:478–91.10.7326/0003-4819-147-7-200710020-00006Suche in Google Scholar PubMed
8. Last AR, Hulbert K. Chronic low back pain: evaluation and management. Am Fam Physician 2009;79:1067–74.10.1080/20786204.2010.10873969Suche in Google Scholar
9. Shiri R, Solovieva S, Husgafvel-Pursiainen K, Taimela S, Saarikoski LA, Huupponen R, et al. The association between obesity and the prevalence of low back pain in young adults: the Cardiovascular Risk in Young Finns Study. Am J Epidemiol 2008;167:1110–9.10.1093/aje/kwn007Suche in Google Scholar PubMed
10. Romero-Sanchez C, Tsou HK, Jan MS, Wong RH, Chang IC, Londoño J, et al. Serum monocyte chemotactic protein-1 concentrations distinguish patients with ankylosing spondylitis from patients with mechanical low back pain. J Spinal Disord Tech 2011;24:202–7.10.1097/BSD.0b013e3181e15cc8Suche in Google Scholar PubMed
11. Weber KT, Satoh S, Alipui DO, Virojanapa J, Levine M, Sison C, et al. Exploratory study for identifying systemic biomarkers that correlate with pain response in patients with intervertebral disc disorders. Immunol Res 2015;63:170–80.10.1007/s12026-015-8709-2Suche in Google Scholar PubMed PubMed Central
12. World Health Organization. Priority Medicines for Europe and the World Update Report, 2013. Available at: http://www.who.int/medicines/areas/priority_medicines/en. Accessed 1 December 2016.Suche in Google Scholar
13. Kelesidis T, Kelesidis I, Chou S, Mantzoros CS. Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med 2010;152:93–100.10.7326/0003-4819-152-2-201001190-00008Suche in Google Scholar PubMed PubMed Central
14. Lim G, Wang S, Zhang Y, Tian Y, Mao J. Spinal leptin contributes to the pathogenesis of neuropathic pain in rodents. J Clin Invest 2009;119:295–304.10.1172/JCI36785Suche in Google Scholar PubMed PubMed Central
15. Kutlu S, Canpolat S, Sandal S, Ozcan M, Sarsilmaz M, Kelestimur H. Effects of central and peripheral administration of leptin on pain threshold in rats and mice. Neuro Endocrinol Lett 2003;24:193–6.Suche in Google Scholar
16. Hu F, Cui Y, Guo R, Chen J, Guo R, Shen N, et al. Spinal leptin contributes to the development of morphine antinociceptive tolerance by activating the STAT3-NMDA receptor pathway in rats. Mol Med Rep 2014;10:923–30.10.3892/mmr.2014.2250Suche in Google Scholar PubMed
17. Rodgers HM, Liban S, Wilson LM. Attenuated pain response of obese mice (B6.Cg-lep(ob)) is affected by aging and leptin but not sex. Physiol Behav 2014;123:80–5.10.1016/j.physbeh.2013.10.007Suche in Google Scholar PubMed
18. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 2009;29:313–26.10.1089/jir.2008.0027Suche in Google Scholar PubMed PubMed Central
19. Heitzer E, Sandner-Kiesling A, Schippinger W, Stohscheer I, Osprian I, Bitsche S, et al. IL-7, IL-18, MCP-1, MIP1-β, and OPG as biomarkers for pain treatment response in patients with cancer. Pain Physician 2012;15:499–510.Suche in Google Scholar
20. Thacker MA, Clark AK, Bishop T, Grist J, Yip PK, Moon LD, et al. CCL2 is a key mediator of microglia activation in neuropathic pain states. Eur J Pain 2009;13:263–72.10.1016/j.ejpain.2008.04.017Suche in Google Scholar PubMed
21. Hu JH, Zheng XY, Yang JP, Wang LN, Ji FH. Involvement of spinal monocyte chemoattractant protein-1 (MCP-1) in cancer-induced bone pain in rats. Neurosci Lett 2012;517:60–3.10.1016/j.neulet.2012.04.026Suche in Google Scholar PubMed
22. Hingtgen CM. A new “kine” of pain: MCP-1 and sensory neuron excitability. Focus on “MCP-1 enhances excitability of nociceptive neurons in chronically compressed dorsal root ganglia”. J Neurophysiol 2006;96:2171–2.10.1152/jn.00611.2006Suche in Google Scholar PubMed
©2017 Walter de Gruyter GmbH, Berlin/Boston
Artikel in diesem Heft
- Frontmatter
- Editorial
- Mass spectrometry or immunoassay: est modus in rebus
- Reviews
- The use of liquid chromatography-tandem mass spectrometry for therapeutic drug monitoring of antibiotics in cancer patients
- Tackling serum folate test in European countries within the health technology assessment paradigm: request appropriateness, assays and health outcomes
- Genetics and Molecular Diagnostics
- Genetic diagnosis of α1-antitrypsin deficiency using DNA from buccal swab and serum samples
- General Clinical Chemistry and Laboratory Medicine
- Serum triglyceride measurements: the commutability of reference materials and the accuracy of results
- Variant peptide detection utilizing mass spectrometry: laying the foundations for proteogenomic identification and validation
- Evaluation of two fully automated immunoassay based tests for the measurement of 1α,25-dihydroxyvitamin D in human serum and comparison with LC-MS/MS
- Parallel diurnal fluctuation of testosterone, androstenedione, dehydroepiandrosterone and 17OHprogesterone as assessed in serum and saliva: validation of a novel liquid chromatography-tandem mass spectrometry method for salivary steroid profiling
- Determination of oxycodone and its major metabolites noroxycodone and oxymorphone by ultra-high-performance liquid chromatography tandem mass spectrometry in plasma and urine: application to real cases
- Identification and quantitation of phosphatidylethanols in oral fluid by liquid chromatography-tandem mass spectrometry
- Relationship between plasma and salivary melatonin and cortisol investigated by LC-MS/MS
- Paramagnetic micro-particles as a tool for rapid quantification of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma by UHPLC-MS/MS
- Measurements of serum non-ceruloplasmin copper by a direct fluorescent method specific to Cu(II)
- The serum concentrations of leptin and MCP-1 independently predict low back pain duration
- Immunoassay screening in urine for synthetic cannabinoids – an evaluation of the diagnostic efficiency
- Cancer Diagnostics
- Study of kallikrein-related peptidase 6 (KLK6) and its complex with α1-antitrypsin in biological fluids
- Cardiovascular Diseases
- A candidate liquid chromatography mass spectrometry reference method for the quantification of the cardiac marker 1-32 B-type natriuretic peptide
- The natriuretic peptide MR-proANP predicts all-cause mortality and adverse outcome in community patients: a 10-year follow-up study
- CASZ1 loss-of-function mutation contributes to familial dilated cardiomyopathy
- Diabetes
- Evaluating new HbA1c methods for adoption by the IFCC and NGSP reference networks using international quality targets
- Infectious Diseases
- Analytical and diagnostic performance of two automated fecal calprotectin immunoassays for detection of inflammatory bowel disease
- Letters to the Editor
- Is fasting necessary for lipid profile determinations? Some considerations from the perspective of the clinical laboratory
- Precision of nonfasting lipid profiles should focus on clinical relevance rather than necessarily obtaining the least variation
- Triglyceride concentrations should be measured after elimination of free glycerol to exclude interindividual variations due to adiposity and fasting status
- Estimation of the reference interval for serum folate measured with assays traceable to the WHO International Standard
- Implausible elevation of peripheral thyroid hormones during therapy with a protein supplement
- Interference in Na+ measurements on the Siemens RAPIDPoint® 500 after nortriptyline intoxication: a case report
- Usefulness of maternal red cell antibodies to predict hemolytic disease of the fetus and newborn and significant neonatal hyperbilirubinemia: a retrospective study
- Improvement of the Sandell-Kolthoff reaction method (ammonium persulfate digestion) for the determination of iodine in urine samples
- Clinical use of targeted high-throughput whole-genome sequencing for a dengue virus variant
Artikel in diesem Heft
- Frontmatter
- Editorial
- Mass spectrometry or immunoassay: est modus in rebus
- Reviews
- The use of liquid chromatography-tandem mass spectrometry for therapeutic drug monitoring of antibiotics in cancer patients
- Tackling serum folate test in European countries within the health technology assessment paradigm: request appropriateness, assays and health outcomes
- Genetics and Molecular Diagnostics
- Genetic diagnosis of α1-antitrypsin deficiency using DNA from buccal swab and serum samples
- General Clinical Chemistry and Laboratory Medicine
- Serum triglyceride measurements: the commutability of reference materials and the accuracy of results
- Variant peptide detection utilizing mass spectrometry: laying the foundations for proteogenomic identification and validation
- Evaluation of two fully automated immunoassay based tests for the measurement of 1α,25-dihydroxyvitamin D in human serum and comparison with LC-MS/MS
- Parallel diurnal fluctuation of testosterone, androstenedione, dehydroepiandrosterone and 17OHprogesterone as assessed in serum and saliva: validation of a novel liquid chromatography-tandem mass spectrometry method for salivary steroid profiling
- Determination of oxycodone and its major metabolites noroxycodone and oxymorphone by ultra-high-performance liquid chromatography tandem mass spectrometry in plasma and urine: application to real cases
- Identification and quantitation of phosphatidylethanols in oral fluid by liquid chromatography-tandem mass spectrometry
- Relationship between plasma and salivary melatonin and cortisol investigated by LC-MS/MS
- Paramagnetic micro-particles as a tool for rapid quantification of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma by UHPLC-MS/MS
- Measurements of serum non-ceruloplasmin copper by a direct fluorescent method specific to Cu(II)
- The serum concentrations of leptin and MCP-1 independently predict low back pain duration
- Immunoassay screening in urine for synthetic cannabinoids – an evaluation of the diagnostic efficiency
- Cancer Diagnostics
- Study of kallikrein-related peptidase 6 (KLK6) and its complex with α1-antitrypsin in biological fluids
- Cardiovascular Diseases
- A candidate liquid chromatography mass spectrometry reference method for the quantification of the cardiac marker 1-32 B-type natriuretic peptide
- The natriuretic peptide MR-proANP predicts all-cause mortality and adverse outcome in community patients: a 10-year follow-up study
- CASZ1 loss-of-function mutation contributes to familial dilated cardiomyopathy
- Diabetes
- Evaluating new HbA1c methods for adoption by the IFCC and NGSP reference networks using international quality targets
- Infectious Diseases
- Analytical and diagnostic performance of two automated fecal calprotectin immunoassays for detection of inflammatory bowel disease
- Letters to the Editor
- Is fasting necessary for lipid profile determinations? Some considerations from the perspective of the clinical laboratory
- Precision of nonfasting lipid profiles should focus on clinical relevance rather than necessarily obtaining the least variation
- Triglyceride concentrations should be measured after elimination of free glycerol to exclude interindividual variations due to adiposity and fasting status
- Estimation of the reference interval for serum folate measured with assays traceable to the WHO International Standard
- Implausible elevation of peripheral thyroid hormones during therapy with a protein supplement
- Interference in Na+ measurements on the Siemens RAPIDPoint® 500 after nortriptyline intoxication: a case report
- Usefulness of maternal red cell antibodies to predict hemolytic disease of the fetus and newborn and significant neonatal hyperbilirubinemia: a retrospective study
- Improvement of the Sandell-Kolthoff reaction method (ammonium persulfate digestion) for the determination of iodine in urine samples
- Clinical use of targeted high-throughput whole-genome sequencing for a dengue virus variant
